Andreas Möller,
Associate Professor,
Group Leader and Head, Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute
Dr. Andreas Möller is Group Leader of the Tumour Microenvironment Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. He is also adjunct Associate Professor with the Faculty of Medicine at the University of Queensland, and the School of Biomedical Science at the Queensland University of Technology. Dr Möller received his doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, followed by postdoctoral training at the University of Berne, Switzerland, and the Peter MacCallum Cancer Center, Melbourne, Australia. Dr Möller is an expert in cancer metastasis and cancer immunology, and now has more than 10 years of experience in the Extracellular Vesicle (EV) field. Based on clinical collaborations, patents in the EV field and commercial partners, his work is focused on gaining a better understanding of the role of EVs in cancer progression and their use as cancer biomarkers.
Cancer-derived Extracellular Vesicles as Early Disease Biomarkers
Wednesday, 14 September 2022 at 09:30
Add to Calendar ▼2022-09-14 09:30:002022-09-14 10:30:00Europe/LondonCancer-derived Extracellular Vesicles as Early Disease BiomarkersExtracellular Vesicles 2022: Biology, Disease and Medicine in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com
Late diagnosis of cancer is a key cause of the high cancer-associated mortality. However, a most cancer progression occurs ‘silently’, associated with no or diffuse symptoms. A non-invasive test, for example using blood, to determine that an individual has an early stage cancer would provide curative therapeutic options and presents an important unmet clinical needs. In this presentation, I will summarize the research approaches in the area of cancer-derived EVs undertaken by my group. I will discuss novel data on how liquid biopsies based on small amounts of blood can determine the presence of early stage cancer and how this can be potentially applied clinically. In detail, we derived a cancer-specific multi-protein EV marker capable of detecting the presence of 8 cancer types in individuals, including those patients with stage I. Confirming the platform independence of the biomarker, we transferred the test to a SERS-based microfluidics platform, and demonstrate the capacity to distinguish patients with benign and malignant conditions. Overall, our biomarker is capable of detecting early stage cancer in the blood of individuals and has various potential applications in reducing cancer-associated mortality.
Add to Calendar ▼2022-09-13 00:00:002022-09-14 00:00:00Europe/LondonExtracellular Vesicles 2022: Biology, Disease and MedicineExtracellular Vesicles 2022: Biology, Disease and Medicine in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-09-14 09:30:002022-09-14 10:30:00Europe/LondonCancer-derived Extracellular Vesicles as Early Disease BiomarkersExtracellular Vesicles 2022: Biology, Disease and Medicine in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com
